2 reports

  • Aug 03, 2017: AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa
  • Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day

Several AAV gene therapy products are in late-stage clinical development, and one product is approved in the EU.

  • Gene Therapy
  • Therapy
  • United States
  • Company Operations
  • Applied Genetic Technologies Corporation
  • GENE THERAPY FOR ACHROMATOPSIA - DRUG PROFILE
  • GENE THERAPY FOR X-LINKED RETINOSCHISIS AND ACHROMATOPSIA - DRUG PROFILE

Evidence in animal models suggests that our gene therapy candidate, delivered as a one-time injection, has the potential to provide long-lasting vision improvement in patients affected by this condition. "

  • Gene Therapy
  • United States
  • Company Operations
  • Product Initiative
  • Applied Genetic Technologies Corporation